



Correction: Arterial hypertension - clinical trials update 2022

Felix Götzinger · Michael Kunz · Lucas Lauder · Michael Böhm · Felix Mahfoud

Published online: 15 July 2022

© The Author(s), under exclusive licence to The Japanese Society of Hypertension 2022

Correction to: *Hypertension Research*

<https://doi.org/10.1038/s41440-022-00931-2>

In the original publication of the article, refs. [11–13] were incorrectly published. The corrected lists are provided below:

The original article has been corrected.

References

11. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al.; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. *N Engl J Med.* 2014;371:993–1004.
12. Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, et al; PARAGON-HF Investigators and Committees. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. *N Engl J Med.* 2019;381:1609–20.
13. Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, McCague K, et al. PIONEER-HF Investigators. Angiotensin-neprilysin inhibition in acute decompensated heart failure. *N Engl J Med.* 2019;380:539–48.